Spencer Feldman

MosunPola improved progression-free survival and response rates over R-GemOx in transplant-ineligible relapsed large B-cell lymphoma.

Appeals, peer-to-peer reviews and external reviews often overturn insurance denials, helping patients access recommended cancer care.

Investigational bispecific antibody pumitamig achieved a 70% response rate and disease control in all evaluable patients with advanced NSCLC.

ASCO 2026 highlighted advances in pancreatic, breast, sarcoma, lung and prostate cancers that may reshape treatment.

FDA approved Cavhanza, a new nilotinib formulation for adults with Ph+ CML that may offer more flexible dosing and easier administration.

Iza-bren improved survival and delayed disease progression versus chemotherapy in previously treated metastatic triple-negative breast cancer.

Giredestrant plus Afinitor improved disease control after later treatment and delayed chemotherapy in ER-positive, HER2-negative breast cancer.

Sac-TMT plus Keytruda helped patients with PD-L1–positive advanced NSCLC live longer without their cancer worsening and increased response rates versus Keytruda alone.

A cancer survivor’s wife created a life transition binder during his treatment to organize medical, financial and household information to access details in emergencies.

FDA approves Decnupaz for adults with BPDCN, with 69.7% of treatment-naïve patients achieving remission in the CADENZA trial.

FDA approved Datroway for unresectable or metastatic triple-negative breast cancer not eligible for PD-1 or PD-L1 therapy with PFS, OS and response rates vs chemotherapy.

ASCO 2026 will highlight biomarker-driven lung cancer care, targeted therapies, ADCs and phase 3 trials shaping precision oncology advances.

The FDA approved Enhertu for certain patients with HER2-positive early-stage breast cancer before and after surgery based on DESTINY trial data.

Jill Winther earned CURE’s 2026 Extraordinary Healer® Award for her leadership, advocacy and dedication to oncology nursing.

Oncology dietitians shared smoothie and turmeric latte recipes to help patients with breast cancer manage nutrition during treatment.

Edward Miskie shares how survivorship can feel isolating, inspiring the Remission Film Festival to spotlight the emotional realities after treatment.

New therapies are beginning to crack KRAS, offering tumor shrinkage and longer survival as researchers work to overcome resistance.

New immunotherapy use before and after surgery improves outcomes, making early symptom recognition and expert care more critical than ever.

New T-cell engagers and ADCs show survival gains in pretreated small cell lung cancer, signaling long-awaited progress and more treatment options for patients.

Gotistobart improved responses and survival versus docetaxel in pretreated squamous NSCLC, offering a potential chemo-free option with durable benefit in some patients.

A tongue cancer survivor and her oncologist discuss lasting side effects, daily management, self-advocacy and emerging treatment approaches.

Libtayo improved survival and safety outcomes vs chemotherapy in advanced NSCLC, with 23% of patients alive at six years in the EMPOWER-Lung 1 trial.

New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients with lung cancer.

Early detection and grade-based care help manage immunotherapy toxicities, with tailored approaches for skin, gastrointestinal and cardiac side effects.

AI is being used across cancer care for prevention, diagnosis, treatment, survivorship and end-of-life support, improving efficiency while posing deskilling and cognitive risks.

Black patients with early-stage lung cancer were less likely to receive curative treatment than White patients, despite all having Medicare coverage, study finds.

Functional precision medicine may help guide faster, more personalized treatment decisions in pediatric brain tumors by testing therapies directly on a patient’s tumor cells.

New FDA approvals target mutations in lung cancer, improving outcomes, while clinicians refine strategies to manage immunotherapy-related side effects.

Keytruda plus weekly paclitaxel improved overall and progression-free survival in platinum-resistant ovarian cancer in the phase 3 KEYNOTE-B96 trial.

An expert explains how immunotherapy, targeted therapy and tumor testing are expanding treatment options for patients with gynecologic cancers.